Prostate cancer is the most commonly diagnosed malignancy among men, but few genetic factors that drive prostate cancer initiation have been identified. The WD repeat domain 77 (Wdr77) protein is essential for cellular proliferation when it localizes in the cytoplasm of epithelial cells at the early stage of prostate development. In the adult prostate, it is transported into the nucleus and functions as a co-regulator of the androgen receptor to promote cellular differentiation and prostate function. This developmental process is reversed during prostate tumorigenesis i.e., Wdr77 is translocated from the nucleus into the cytoplasm to drive proliferation of prostate cancer cells. In this study, we used in vivo genetic studies to investigate the role of Wdr77 in prostate tumorigenesis. We found that prostate-specific deletion of Wdr77 abolished prostate tumor initiation induced by loss of the tumor suppressor Pten. Mechanistically, Wdr77 ablation inhibited E2F3 activation and enhanced TGFb signaling, leading to attenuated cellular proliferation induced by loss of Pten. These findings establish an essential role of Wdr77 for prostate tumor initiation.

L'EGFR est un récepteur transmembranaire à activité tyrosine kinase (TK) qui transduit des signaux de prolifération et de survie cellulaire. Dans les cancers du poumon, son activité est fréquemment dérégulée par surexpression et/ou par mutation au niveau de son domaine TK. Ces mutations sont principalement de deux types (EGFR-L858R et EGFR-Del19) et sont dites activatrices car elles induisent une activation constitutive des signalisations oncogéniques de l'EGFR. Elles sont aussi un facteur prédictif de réponse aux EGFR-TKIs qui inhibent spécifiquement ce récepteur. P14ARF est un suppresseur de tumeur qui restreint la prolifération cellulaire et maintient la stabilité génomique. Nous avons décrit son inactivation dans les cancers du poumon et démontré que son expression freine leur développement. Nos résultats récents montrent que l'expression de p14ARF est inhibée dans une très grande majorité d'adénocarcinomes pulmonaires présentant une mutation activatrice de l'EGFR. Sur la base de ces résultats nous avons émis l'hypothèse que l'inhibition de l'expression de p14ARF contribuerait à l'expansion clonale des tumeurs porteuses d'un EGFR muté. P14ARF pourrait ainsi être un frein à l'activité oncogénique de l'EGFR.Dans différents modèles d'adénocarcinomes pulmonaires exprimant un mutant EGFR-L858R nous montrons que l'expression transitoire de p14ARF active une signalisation pro-apoptotique dépendante de STAT3 et de Bcl2. En retour, l'EGFR inhibe l'expression de p14ARF et bloque ses fonctions pro-apoptotiques. Nous montrons aussi que l'activation de l'EGFR (sauvage ou muté) inhibe l'expression de p14ARF à un niveau transcriptionnel. Ceci implique une translocation nucléaire de l'EGFR contrôlée par les PI3Ks de classe III (Vps34) et la fixation de l'EGFR sur le promoteur de ARF. L'ensemble de ces travaux identifie pour la première fois un lien fonctionnel entre les voies de signalisation de l'EGFR et de p14ARF. Ils mettent en évidence un nouveau mécanisme de progression tumorale par lequel une signalisation nucléaire de l'EGFR inactive le suppresseur de tumeur p14ARF afin de permettre la croissance tumorale. / EGFR is a transmembrane tyrosine kinase (TK) receptor which activates proliferative and survival signals. In lung cancer, its activity is frequently deregulated by overexpression and/or mutation in its TK domain. These mutations are mainly of two types (L858R and Del19) and are called « driver mutations » because they induce constitutive activation of EGFR oncogenic signaling. They also represent a predictive responsive factor to EGFR TKIs that specifically inhibit this receptor. P14ARF is a tumor suppressor that restricts cellular proliferation and maintains genomic stability. We described its inactivation in lung cancer and demonstrated that its expression inhibits their development. Our recent results show that the expression of p14ARF is inhibited in a majority of lung adenocarcinomas expressing an activating EGFR mutation. Based on these results we hypothesized that inhibition of p14ARF expression contributes to clonal expansion of mutated EGFR-bearing tumor. P14ARF could be a break to EGFR oncogenic activity.In different models of lung adenocarcinoma expressing a L858R EGFR mutant we show that transient expression of p14ARF activates a pro-apoptotic STAT3/Bcl-2-dependent signaling pathway. In turn, EGFR inhibits the expression of p14ARF and blocks its pro-apoptotic function. We also show that EGFR (wild type or mutated) activation inhibits the expression of p14ARF at the transcriptional level. This implies a nuclear translocation of EGFR controlled by Class III PI3K (Vps34) and its fixation to the ARF promoter. This work identifies for the first time a functional link between EGFR and p14ARF signaling pathways. They highlight a new mechanism of tumor progression by which a nuclear EGFR signaling inactivates the tumor suppressor p14ARF to allow tumor growth.

Mutações com ganho de função do proto-oncogene Ras se encontram entre umas das mais freqüentes modificações em cânceres humanos, além disso, tumores com esses caracterísitcas possuem, em geral, mau prognóstico. O objetivo inicial desta tese foi estudar novos mecanismos anti-proliferativos disparados por dois agentesmitogênicos, FGF2 (\"Fibroblast Growth Factor 2\") e PMA (\"Phorbol-12-Myristate-13-Acetate\", (um diéster de forbol), sobre células de camundongos transformadas por Ras e refratárias a apoptose. Para isso utilizamos duas linhagens celulares: uma linhagem naturalmente trtansformada por uma ampliação do gene K-Ras, que é derivada de um tumor de córtex adreno-cortical de camundongo e é denominada Y1, e uma sublinhagem derivada de Balb/c-3T3, transformada em laboratório com o oncogene H-RasV12 humano. A fim de se elucidar o mecanismo de ação de FGF2, foram selecionadas e caracterizadas múltiplas sublinhagens clonais resistentes a FGF2, derivadas das linhagens parentais Y1 e B61. Mostramos assim, que o FGF2 exerce um forte efeito negativo, de forma que os clones resistentes ao mesmo tendem a perder aos altos níveis de expressão da proteína Ras. Mostramos ainda que esses células passam a ser dependentes de FGF2 para crescer em cultura, perdem a capacidade de crescimento em suspensão e são menos tumorigênicas quando comparadas às células parentais. Em uma segunda etapa, caracterizamos o efeito citotóxico de PMA sobre células transformadas por Ras, e vimos que esse efeito é mais acentuado para células transformadas por K-Ras, mas é nulo sobre células imortalizadas não tumorigênicas. Mostramos ainda que esse efeito passa pela ativação da via de PKC. A inibição da proliferação por PMA se deve, ao menos parcialmente, à indução de senescência nessas células. De forma semelhante ao que foi para o estudo com FGF2, foram selecionados clones resistentes a PMA, derivados de Y1. Os clones obtidos se mostraram muito instáveis, pouco resistentes a PMA e dependentes de FGF2 para crescer. Todos os clones testados se mostram tumorigênicos, entretanto, apresentaram maior tempo de latência, estaticamente diferente da célula parental, Y1. Assim, neste trabalho, mostramos que duas substâncias, com caráter mitogênico e potencialmente oncogênico, são capazes de inibir seletivamente a proliferação de células transformadas por Ras, uma vez que elas não têm efeito sobre células não transformadas. Desvendar os mecanismos que causam a citotoxidade dessas substâncias deve trazer informações relevantes com possibilidades de impacto em terapia de tumores dependentes dos oncogenes Ras. / Amplification and gain of function mutations in ras proto-oncogenes are frequent genetic lesions in human cancers of bad prognostic. This thesis aimed to investigate novel anti-proliferative mechanisms induced by two mitogens, FGF2 (\"Fibroblast Growth Factor 2\") and PMA (\"Phorbol-12-Myristate-13-Acetate\", a phorbol diester), in murine cell lines transformed by ras and resistant to apoptosis. To this end, we took two different mouse malignant cell lines: Y1, a cell line derived from an adrenal tumor, naturally transformed by K-ras amplification and another one, 3T3-B61, obtained by transformation of Balb-3T3 fibroblasts with the H-rasV12 oncogene. To elucidate FGF2 mechanisms of action, we selected, isolated and characterized clonal sublines resistant to FGF2 from both Y1 and 3T3-B61 parental lines. FGF2-resistant clones are rare normal-like revertant sublines that no longer display Ras over expression, dependent on FGF2 for growth, do not grow in suspension cultures and exhibit low tumorigenicity in Nude mice. These results show that FGF2 exerts a strong selective pressure against ras-transformed cells, inducing senescence and irreversibly blocking proliferation. Differently from FGF2 , PMA citotoxic effect is completely dependent on PKC activity. In addition, PMA is highly toxic to K-Ras transformed Y1 cells, poorly toxic to H-Ras-transformed 3T3-B61 cells and not toxic to immortalized non tumorigenic cell lines. Attempts to select PMA-resistant cells fropm Y1 parental line have yielded very rare, highly clonal sublines, dependent on FGF2 for proliferation. In conclusion, two mitogens, FGF2 and PMA, can selectively inhibit Ras-driven proliferation, a phenomenon of great interest for biology and therapy of tumors dependent on ras oncogenes.

CoordenaÃÃo de AperfeiÃoamento de Pessoal de NÃvel Superior / In search for a better understanding of the biology of tumors, molecular markers related to proliferation, resistance and apoptosis have been intensively studied in the different types of cancer. These markers can help on the elucidation of more specific therapeutic targets for the treatment of various tumors. It was observed that stomach cancer is the second most frequent cause of death in the world. In Brazil, this tumor is among the five major causes of death by cancer and the adenocarcinomas are held responsible for about 95% of all cases. For that matter, the expression of KI-67, PCNA, p53, bcl-2 and c-myc were evaluated independently and in a combined form in stomach adenocarcinomas. Thus, KI-67 and PCNA were confronted in order to determine which one would pose as a better cellular proliferation marker. Finally, a DNA extraction tecnique using CTAB was implemented on tumor tissue as well as the molecular analysis of the p53 gene by SSCP. The positive results were compared with those obtained by the imonohistochemistry analysis. The tumors were collected in surgical procedure, processed and classified histopathologically. The markers were detected by the imunohistochemical method SABP. The DNA was extracted by the CTAB method and the exons 5, 7 and 8/9 of the p53 gene analyzed by SABP. Some of the samples were obtained from biopsy arquives. The age range of the patients was between 61 and 70 years, with 48,1% of the tumors presenting an intestinal origin, 40,7% were diffuse and the other 11,2% were mixed. According to the location, 50% of the tumors were found to be proximal. 41,1% of the tumors were found to be in a low stage (I â IIIA), 44,8% in a high stage (IIIB â IV) and 13,8% were not staged. The imunohistochemical results indicated that KI-67 is the best marker to estimate cellular proliferation in stomach adenocarcinomas. In an independent manner, the tumors showed an 89,3% positivity for KI-67, 62,5% for PCNA, 50% for p53, 60,7% for bcl-2 e 66,7% for c-myc. According to the staging, the difference was significant only to p53 (p = 0,02), with a 66,7% positivity to the tumors in low stage and 16,7% for the ones on a high stage. When evaluated in a combined form, the associations of KI-67+/p53- (p=0,012) (66,67%) and c-myc+/p53- (p=0,02) (63,64%) both for the high stage tumors, were found to be significant. The DNA extraction technique applied to the tumor tissue was found to be satisfactory. For the SSCP analyses, five patients had mutation on the exon 5 (3) and on the exon 7 (2). Based on that, we may conclude that KI-67 is the best marker to access the proliferation of the stomach adenocarcinomas and that there are two proliferation activation pathways: one being dependent and the other independent of the p53 gene. / Na busca de um melhor entendimento da biologia dos tumores, marcadores moleculares relacionados à proliferaÃÃo, resistÃncia e apoptose tÃm sido intensamente pesquisados nos diferentes tipos de cÃncer. Estes marcadores podem auxiliar no estudo de alvos terapÃuticos mais especÃficos para cada tipo de tumor. O cÃncer de estÃmago à a segunda causa de Ãbito mais observado no mundo. No Brasil, este tumor està entre as cinco localizaÃÃes primÃrias mais comuns de Ãbitos por cÃncer, sendo os adenocarcinomas responsÃveis por 95% dos casos. Dessa forma, foi avaliada a expressÃo dos marcadores KI-67, PCNA, p53, bcl-2 e c-myc de forma independente e combinada em adenocarcinomas gÃstricos. TambÃm foi avaliado qual dos marcadores, KI-67 ou PCNA, era mais indicado para acessar a proliferaÃÃo celular. AlÃm disso, foi implantada a tÃcnica de extraÃÃo de DNA de tecido tumoral com CTAB e anÃlise molecular pelo SSCP do gene p53, sendo os resultados positivos comparados com os resultados da imunohistoquÃmica. Os tumores foram coletados em cirurgia, processados e classificados histopatologicamente. Os marcadores foram detectados pelo mÃtodo de imunohistoquÃmica SABP. Foi realizada a extraÃÃo de DNA pelo mÃtodo do CTAB, sendo os Ãxons 5, 7 e 8/9 do gene p53 analisados por SSCP. Algumas amostras foram obtidas de arquivo de biopsia. A faixa etÃria dos pacientes encontrava-se entre 61 e 70 anos de idade, com 48,1% dos tumores do tipo intestinal, 40,7% difusos e 11,2% mistos e com 50% localizados no sÃtio proximal. Em relaÃÃo ao estadiamento, 41,4% dos tumores apresentavam-se no grau baixo (I â IIIA), 44,8% no altorisco (IIIB â IV) e 13,8% sem estadiamento. De acordo com os achados imunohistoquÃmicos, os resultados sugerem que o marcador mais indicado para estimar a proliferaÃÃo celular nos adenocarcinomas gÃstricos à o KI-67. De forma independente os tumores apresentaram positividade em 89,3% para KI-67, 62,5% para PCNA, 50% para p53, 60,7% para bcl-2 e 66,7% e para c-myc. De acordo com o estadiamento, a diferenÃa foi significativa apenas para p53 (p = 0,02), com positividade de 66,7% nos tumores de baixo risco (I â IIIA) e 16,7% nos de altorisco. Quando avaliadas de forma combinada, as associaÃÃes significativas foram entre KI-67+/p53- (p=0,012) nos tumores de alto risco (66,67%) e c-myc+/p53- (p=0,02) tambÃm nos tumores de altorisco (63,64%). A tÃcnica aplicada para a extraÃÃo do DNA do tecido tumoral foi satisfatÃria. Para o SSCP, cinco pacientes apresentaram mutaÃÃo para o Ãxon 5 (3) e Ãxon 7 (2). Com isso, concluÃmos que o marcador mais indicado para acessar a proliferaÃÃo à o KI-67 e que existem duas vias de ativaÃÃo da proliferaÃÃo nos adenocarcinomas gÃstricos: uma dependente de p53 e outra independente de p53.

CoordenaÃÃo de AperfeiÃoamento de Pessoal de NÃvel Superior / The Epstein-Barr virus (EBV) has been related to the tumorigenesis of the gastric carcinomas, varying from 1.3-19.3% according to the studied population. Several studies have demonstrated strong evidences of its relation in this process, such as the monoclonality of the viral genome and its the presence in almost all tumor cells. However, most of the mechanisms used by the virus to control this process are still unknown. In this context, the present study aimed to investigate the frequency of the EBV and the association with the BCL-2, BAX and c-MYC proteins. Therefore, 100 cases of gastric carcinoma (67 males and 33 females), obtained from two hospitals in Fortaleza, were assessed to detect the EBV by PCR and in situ hybridization (aimed to the EBER1 transcript) using the standard method and GenPointÂ. Immunohistochemistry technique was done to evaluate the expression of the referred cellular proteins, by streptavidin-biotin-peroxidase method. The distribution by sex, age, tumor anatomic site and the histopathologic analysis, in general, reproduced the pattern of the world scientific bibliographies. Regarding virus detection by in situ hybridization, 8 (8%) cases were positive, 6 of these had shown diffuse pattern of staining, and 2 had demonstrated focal pattern. From 100 cases, only 2 presented infected lymphocytes. In general, the EBV demonstrated higher association with: males (87.5%[p=0.265]), tumors situated in the cardia (37.5% [p=0.549]), advanced stage (IIIB and IV), intestinal type (87.5%[p=0.136]), and moderately differentiated (75%).There were no EBV-positive cases which exhibited BCL-2 staining. Although the BAX and the c-MYC (nuclear) proteins have demonstrated significant positivity index and scores averages in the EBV-positive group, these were lower than the values of the EBV-negative group, notably the c-MYC nuclear protein (Mann-Withney test LI p=0.039 and HS p=0.045). The cytoplasmic staining of the c-MYC protein revealed slightly higher staining values in the EBV-positive group. The balance between the BCL-2 and BAX proteins demonstrated that the majority of the evaluated cases had exhibited apoptosis-orientation, however 62.3% of the EBV-positive cases exhibited equilibrium between these proteins. Twenty-nine cases (28 negative and 1 positive) were submitted to the biotinyl tyramide system (in situ hybridization method - GenPointÂ), demonstrating the same results obtained by the standard technique. From the 61 cases assessed by PCR, 35 (57.4%) were positive, being verified a low concordance index (kappa = -0.026 [Â0.069]) with the standard in situ hybridization technique. The 30bp deletion of LMP1 gene was investigated in 24 out of 35 positive cases, being verified in 37.5% of these. The results obtained in the present study, concerning the EBV frequency and the correlation with clinic-histopathologic data, reproduced findings of researches done in several world regions. The correlation with the proteins suggests that in vivo the virus is not related to the overexpression of BCL-2 and c-MYC (nuclear) that could act in synergism to promote the tumor development. The suppression of the BAX expression might represent a viral mechanism for apoptosis inhibition. The results of the cytoplasmic c-MYC point to a possible involvement of the EBV with transport mechanisms of the nuclear membrane, resulting in its accumulation in the cytoplasm. The low frequency of infected lymphocytes indicates that they are not the main responsible of the high number of positivity in the PCR technique. It could be, at least in part, due to the infected normal and/or pre-neoplastic epithelium, suggesting a new latency pattern which not express the EBER1. / O vÃrus Epstein-Barr (EBV) tem sido associado com a tumorigÃnese dos adenocarcinomas gÃstricos, variando entre 1,3-19,3% de acordo com a populaÃÃo estudada. Diversos estudos tÃm demonstrado importantes evidÃncias do envolvimento do EBV nesse processo, tais como a monoclonalidade do genoma viral e a presenÃa do vÃrus em quase todas as cÃlulas tumorais do sitio primÃrio e em cÃlulas metastÃticas. No entanto, os mecanismos utilizados pelo vÃrus para orquestrar a transformaÃÃo tumoral, ainda nÃo foram totalmente elucidados. Neste contexto, o presente estudo objetivou investigar a freqÃÃncia do EBV e a associaÃÃo com as proteÃnas BCL-2, BAX e c-MYC. Para tanto, 100 casos de adenocarcinomas gÃstricos (67 homens e 33 mulheres), obtidos de dois hospitais de Fortaleza, foram analisados quanto à presenÃa do EBV, detectado atravÃs das tÃcnicas de PCR e de hibridaÃÃo in situ (direcionada ao transcrito viral EBER1) pelo mÃtodo usual e GenPointÂ. Procedeu-se tambÃm, estudo imuno-histoquÃmico das referidas proteÃnas celulares, atravÃs do mÃtodo da estreptoavidina-biotina-peroxidase. A distribuiÃÃo por sexo, idade, sÃtio anatÃmico do tumor e as anÃlises histopatolÃgicas, de modo geral, reproduziram as tendÃncias da literatura mundial. Pela tÃcnica de hibridaÃÃo in situ, 8 (8%) casos foram positivos, 6 destes apresentaram marcaÃÃo difusa e 2 apresentaram marcaÃÃo focal. Apenas 2 apresentaram linfÃcitos infectados. De modo geral, o EBV apresentou maior associaÃÃo com o sexo masculino (87,5% [p=0,265]), com tumores situados na cÃrdia (37,5% [p=0,549]), de estadiamento avanÃado (IIIB e IV), do tipo intestinal (87,5% [p=0,136]) e moderadamente diferenciados (75%). Nenhum dos casos EBV-positivos exibiram marcaÃÃo para BCL-2. Embora as proteÃnas BAX e c-MYC (nuclear) apresentaram Ãndices de positividade e mÃdias de escores significativos no grupo EBV-positivo, estes foram inferiores aos valores do grupo EBV-negativo, sobretudo a proteÃna c-MYC nuclear (Teste de Mann-Withney LI p=0,039 e HS p=0,045). A marcaÃÃo citoplasmÃtica da proteÃna c-MYC revelou valores de marcaÃÃo discretamente superiores no grupo EBV-positivo. O balanÃo entre as proteÃnas BCL-2 e BAX demonstrou que a maioria dos casos estudados apresentavam tendÃncia à apoptose, mas 62,5% dos casos EBV-positivos exibiram um equilÃbrio. Vinte e nove casos (28 negativos e 1 positivo) foram submetidos a outro mÃtodo de hibridaÃÃo in situ que emprega o sistema da biotinil-tiramida (GenPointÂ),demonstrando resultados idÃnticos aos obtidos pela tÃcnica convencional. De 61 casos analisados atravÃs da tÃcnica de PCR, 35 (57,4%) foram positivos, sendo constatado um baixÃssimo Ãndice de concordÃncia (kappa = -0,026 [Â0,069]) com a tÃcnica de hibridaÃÃo in situ. Em 24/35 casos positivos, a deleÃÃo de 30pb do gene LMP1 foi investigada, sendo constatada em 37,5% destes. Os resultados obtidos no presente estudo quanto à freqÃÃncia do EBV e a correlaÃÃo com critÃrios clÃnico-histopatolÃgicos, reproduziram os achados de estudos realizados em diversas partes do mundo. A correlaÃÃo com as proteÃnas sugere que in vivo, o vÃrus nÃo esteja relacionado com a expressÃo de BCL-2 e de c-MYC (nuclear), que poderiam atuar em sinergismo favorecendo o desenvolvimento tumoral. A supressÃo da expressÃo de BAX, pode representar um mecanismo viral para inibiÃÃo da apoptose. Os resultados da c-MYC citoplasmÃtica apontam para um possÃvel envolvimento do EBV com mecanismos de transporte da membrana nuclear, determinando o acÃmulo da proteÃna no citoplasma. A baixa freqÃÃncia de linfÃcitos infectados indica que os mesmos nÃo sÃo os principais responsÃveis pela elevada positividade da tÃcnica de PCR, devendo ser ao menos em parte, decorrente de epitÃlio normal e/ou prÃ-neoplÃsico infectado sugerindo um padrÃo de latÃncia que nÃo expresse EBER1.

CoordenaÃÃo de AperfeiÃoamento de Pessoal de NÃvel Superior / The present study aimed to evaluate the expression of genes involved in the tumorigenic process and in the chemoresistance mechanisms of the astrocytic tumors. A clinical and epidemiological analysis, histopathological evaluation and immunohistochemical study of the proteins Ki-67, c-Myc, GFAP, p53, p21WAF1/CIP1, p27KIP1, Bcl-2, Bax, EGFR, erbB-2, p21Ras, MGMT, GSTπ, TS and TopoIIα using streptoavidin-biotin-peroxidase method were performed in 55 different graduations of astrocytomas (WHO) (13 grade I, 14 grade II, 7 grade III, 21 grade IV) and 05 samples of non-tumoral tissue (control group). The distribution by age, sex and tumoral localization of astrocytomas patients in Fortaleza reproduced, in a general way, the worldwide trends. The histopathological findings evaluated with semiquantitative criteria confirmed the classification parameters for astrocytomas established by WHO. The stain for Ki-67 antigen increased as according to astrocytic tumors progression; its detection in more than 8.0% of the tumoral cells distinguished Astrocytomas Grade IV, labeled index between 1.5 and 8.0% differentiated Astrocytomas Grade III and values below 1.5% discriminated low-grade tumors (I and II). The TopoIIα and c-Myc (nuclear) expression demonstrated association with cellular proliferation in astrocytomas, however not in a exclusive way. The c-Myc protein cytoplasmic positive index was bigger among high-grade tumors (71.43%), with maximum expression scores in Astrocytomas Grade IV (LI mean=15.57; H mean=24.42). In general, 76.9% of the Astrocytomas Grade IV tumoral cells revealed moderate positive index for GFAP. The positive index and expression scores for p53 and p27KIP1 (nuclear and cytoplasmic) proteins showed a tendency to increase with the astrocytic tumors progression, while the p21WAF1/CIP1 tumor suppressor detection demonstrated opposite orientation (except in grade IV). The percentage of Bcl-2 and Bax positive tumors increased in accordance with histological grade of astrocytomas, with general positive index of 43.26% and 24.67%, respectively. Bcl-2 staining scores demonstrated propensity to addition according to tumoral evolution, while the scores for Bax was similar in all graduations. The erbB2 protein expression was evidenced only between Astrocytomas Grade IV (positive index=14.28%), while the overexpression of EGFR protein was distinguished in grade I and IV astrocytic tumors, with respectively 46.15% and 61.90% of positive cases. p21Ras protein detection was preponderant in Astrocytomas Grade II (positive index=37.71%), being absent in high-grade tumors (III and IV). The EGFR overexpression and p53 mutation configured mutually exclusive events in astrocytomas tumorigenesis, as well as p21Ras protein and ErbB receptors family overexpression. High positive index for enzymes MGMT, GSTπ and TS was evidenced in astrocytic tumors. MGMT expression scores were high and constant among different histological categories, including non-tumoral specimens (LI mean = 69.43). GSTπ scores demonstrated tendency to reduction in accordance with malignant evolution of astrocytomas, while the values for TS reached higher levels on Astrocytomas Grade IV (H mean=63.33). TopoIIα positive index demonstrated inclination to augment in agreement with the progression of astrocytic tumors, whereas the staining scores had been similar in grade II, III and IV astrocytomas (LI mean=27.71). The results obtained by current investigation indicated Ki-67 antigen as the best cell proliferation marker. The p53 mutation configured an initial and relevant event in astrocytomas, as well as potential indicative of tumor progression. p21WAF1/CIP1 tumor suppressor detection represented important resource for deduction of functional situation of p53 gene, while the p27KIP1 functional activation was not compromised by astrocytomas tumorigenic process. Astrocitomas Bcl-2/Bax ratio denoted increasing of cellular survival orientation in accordance with malignant evolution of these tumors. p21Ras protein overexpression was distinguished as a grade II typical molecular event and a virtual marker of tumor not-progression. c-Myc protein cytoplasmic accumulation configured initial and significant phenomenon in astrocytomas tumorigenesis, being a direct reflex of the nuclear expression of c-myc gene and the tumoral malignance. The combined analysis of the investigated molecular markers confirmed p53 gene mutation as the main tumorigenic pathway of astrocytomas, even though EGFR overexpression has been the predominant alteration in grade IV tumors and the c-myc gene expression has represented a distinct and alternative molecular pathway to different tumor graduations. The remarkable presence of MGMT, GSTπ and TS enzymes configured virtual indication of chemoresistance for many antineoplastic agents, while the high expression of TopoIIα revealed this enzyme as a potential therapeutic target in the astrocytic tumors. / O presente estudo objetivou avaliar a expressÃo de genes envolvidos no processo tumorigÃnico e nos mecanismos de quimiorresistÃncia dos tumores astrocÃticos. Procedeu-se anÃlise clÃnico-epidemiolÃgica, avaliaÃÃo histopatolÃgica e estudo imuno-histoquÃmico das proteÃnas Ki-67, c-Myc, GFAP, p53, p21WAF1/CIP1, p27KIP1, Bcl-2, Bax, EGFR, erbB-2, p21Ras, MGMT, GSTπ, TS e TopoIIα pelo mÃtodo da estreptoavidina-biotina-peroxidase em 55 astrocitomas de diferentes gradaÃÃes (OMS) (13 grau I, 14 grau II, 7 grau III e 21 grau IV) e 05 amostras de tecido cerebral nÃo-tumoral (grupo controle). A distribuiÃÃo por idade, por sexo e pela localizaÃÃo tumoral dos portadores dessas neoplasias reproduziu, de um modo geral, as tendÃncias mundiais. Os achados histopatolÃgicos avaliados segundo critÃrios semiquantitativos confirmaram os parÃmetros de classificaÃÃo dos astrocitomas estabelecidos pela OMS. A marcaÃÃo para o antÃgeno Ki-67 aumentou conforme a progressÃo dos tumores astrocÃticos, sendo que sua detecÃÃo em mais de 8,0% das cÃlulas tumorais distinguiu os Astrocitomas Grau IV, Ãndices entre 1,5 e 8,0% diferenciaram os Astrocitomas Grau III e valores abaixo de 1,5% discriminaram os tumores de baixo grau (I e II). A expressÃo das proteÃnas TopoIIα e c-Myc (nuclear) demonstraram associaÃÃo com a proliferaÃÃo celular nos astrocitomas, todavia de maneira nÃo exclusiva. A positividade citoplasmÃtica para proteÃna c-Myc foi maior entre os tumores de alto grau (71,43%), com escores de expressÃo mÃximos nos Astrocitomas Grau IV (LI mÃdio=15,57; H mÃdio=24,42). Em mÃdia, 76,9% das cÃlulas tumorais dos Astrocitomas Grau IV manifestaram moderada positividade para GFAP. A positividade e os escores de marcaÃÃo para as proteÃnas p53 e p27KIP1 (nuclear e citoplasmÃtica) demonstraram tendÃncia de aumento conforme a progressÃo dos tumores astrocÃticos, enquanto a detecÃÃo do p21WAF1/CIP1 mostrou orientaÃÃo oposta (exceto no grau IV). A porcentagem de tumores positivos para Bcl-2 e Bax aumentou conforme a gradaÃÃo dos astrocitomas, com positividade geral de 43,26% e 24,67%, respectivamente. Os escores de marcaÃÃo para Bcl-2 demonstraram propensÃo ao acrÃscimo segundo a evoluÃÃo tumoral, enquanto os Ãndices para Bax foram semelhantes nas diversas graduaÃÃes. A expressÃo da proteÃna erbB2 foi evidenciada apenas entre os Astrocitomas Grau IV (positividade=14,28%), enquanto a superexpressÃo da proteÃna EGFR destacou-se nos tumores astrocÃticos dos graus I e IV, com respectivamente 46,15% e 61,90% de casos positivos. A detecÃÃo da proteÃna p21Ras foi preponderante entre os Astrocitomas Grau II (positividade=37,71%), estando ausente nos tumores de alto grau (III e IV). A superexpressÃo do EGFR e a mutaÃÃo do p53 configuraram eventos mutuamente exclusivos nos astrocitomas, assim como a superexpressÃo da proteÃna p21Ras e dos receptores da famÃlia ErbB. Constatou-se elevada positividade para as enzimas GSTπ, TS e MGMT nos tumores astrocÃticos. Os Ãndices de expressÃo da MGMT mostraram-se elevados e constantes entre as diferentes categorias histolÃgicas, incluindo os espÃcimes nÃo-tumorais (LI mÃdio=69,43). Os escores para GSTπ demonstraram tendÃncia à reduÃÃo de acordo com evoluÃÃo maligna dos astrocitomas, enquanto os Ãndices para TS atingiram nÃveis mais elevados entre os Astrocitomas Grau IV (H mÃdio=63,33). A positividade para enzima TopoIIα apresentou propensÃo ao aumento conforme a progressÃo dos tumores astrocÃticos, ao passo que os escores de marcaÃÃo foram semelhantes nos astrocitomas dos graus II, III e IV (LI mÃdio=27,71). Os resultados obtidos pela corrente investigaÃÃo apontaram o antÃgeno Ki-67 como o melhor marcador de proliferaÃÃo celular nos tumores astrocÃticos. A mutaÃÃo do p53 configurou evento inicial, relevante e potencialmente indicador de progressÃo tumoral nos astrocitomas. A detecÃÃo do supressor tumoral p21WAF1/CIP1 representou importante recurso para a deduÃÃo da situaÃÃo funcional do gene p53, enquanto a ativaÃÃo funcional do p27KIP1 nÃo foi comprometida pelo processo tumorigÃnico nos astrocitomas. A relaÃÃo Bcl-2/Bax nos astrocitomas revelou a crescente orientaÃÃo à sobrevida celular conforme a evoluÃÃo maligna desses tumores. A superexpressÃo da proteÃna p21Ras destacou-se como um evento molecular tÃpico do grau II e virtual indicador de nÃo-progressÃo tumoral. O acÃmulo citoplasmÃtico da proteÃna c-Myc configurou fenÃmeno inicial e significante na tumorigÃnese dos astrocitomas, sendo reflexo direto da expressÃo nuclear do gene c-myc e da malignidade tumoral. A anÃlise conjunta dos marcadores moleculares investigados confirmou a mutaÃÃo do gene p53 como a principal via tumorigÃnica dos astrocitomas, ainda que a superexpressÃo do EGFR tenha sido a alteraÃÃo predominante nos tumores do grau IV e a expressÃo do gene c-myc tenha representado uma via molecular distinta e alternativa Ãs demais nas diferentes graduaÃÃes tumorais. A marcante presenÃa das enzimas MGMT, GSTπ e TS configurou virtual indicaÃÃo de quimiorresistÃncia para diversos agentes antineoplÃsicos, enquanto a elevada expressÃo da TopoIIα revelou esta enzima como potencial alvo terapÃutico nos tumores astrocÃticos.

Le métabolisme cellulaire est la source principale d’énergie et les cellules cancéreuses ont un métabolisme différent des cellules non transformées. La cellule tumorale a tendance à éviter l’activité mitochondriale et ainsi la phosphorylation oxydative, pour lui préférer la voie de la glycolyse pour la production d’énergie (Effet Warburg). Cette altération du métabolisme est si bénéfique pour les cellules en croissance que cela favorise la croissance tumorale et supprime la réponse immunitaire anticancéreuse. La spécificité de ce métabolisme en fait une cible intéressante pour le développement de thérapies anticancéreuses. Mon travail de thèse comporte deux parties. La première partie décrit que lorsque les cellules cancéreuses sont forcées à utiliser la voie mitochondriale comme source d’énergie à travers l’oxydation phosphorylative, elles initient un mécanisme antioxydant pour tolérer les effets délétères des espèces oxygénées réactives (EOR ou ROS pour reactive oxygene species) produites au cours de l’activité mitochondriale. La stimulation mitochondriale entraîne l’activation de la voie de signalisation ERK5-MEF2, et cette dernière engendre un mécanisme antioxydant de deux façons.Initialement, nous avons observé que MEF2 régule positivement l’expression de miR23a, et ce dernier inhibe l’expression de KEAP1. Cette protéine est responsable de la dégradation ubiquitine dépendante de NRF2, un régulateur clé de la réponse antioxydante cellulaire. L’inhibition de KEAP1 empêche la dégradation cytoplasmique de NRF2. Consécutivement à cela la concentration cytoplasmique en NRF2 augmente ce qui engendre sa translocation dans le noyau où il se lie à une séquence élément de réponse antioxydant (ARE) dans la région promotrice de nombreux gènes antioxydants, initiant ainsi leur transcription. Plus tard nous avons observé que l’activation de la voie ERK5-MEF2 induisait directement la synthèse de novo de NRF2, induisant sa translocation nucléaire et un mécanisme antioxydant. L’inhibition de la voie ERK5-MEF2 altère la réponse antioxydante, sensibilisant ainsi les cellules au stress oxydant.La seconde partie de mon travail a exploré les mécanismes à l’origine des effets hypolipémiants du dichloroacétate (DCA). Le DCA est une petite molécule qui inhibe la PDK1 et permet au pyruvate d’entrer dans la mitochondrie. Il a été utilisé en clinique dans le passé pour baisser les taux plasmatiques de cholestérol mais le mécanisme n’était pas clair et nous l’avons décris. Le DCA force les cellules à entrer en oxydation phosphorylative ce qui active la voie ERK5-MEF2. Cette voie augmente directement l’expression du LDLR (Low Density Lipoprotein Receptor ; récepteur aux lipoprotéines de basse densité) qui permet l’endocytose des LDL riches en cholestérol qui sont responsables de la plupart des maladies cardiovasculaires. L’inhibition de cette voie supprime l’afflux de lipides et par conséquent serait une cible intéressante pour de futures recherches puisque de hauts taux de cholestérols sont directement corrélés avec une augmentation du risque d’athérosclérose et de toutes les complications mortelles qu’il entraine.Notre prochain objectif est d’explorer les autres mécanismes cellulaires régulés par la voie ERK5-MEF2. Sur la base de nos résultats préliminaires, nous proposons que cette voie non seulement régule l’expression du LDLR mais aussi celle de nombreux autres gènes qui sont impliqués directement ou indirectement dans le métabolisme des lipides. / Cellular metabolism is the main source of energy and cancer cells has different metabolism than non-transformed cells. Tumor cell tends to avoid mitochondrial activity and oxidative phosphorylation (OXPHOS) and prefer glycolysis for energy production (Warburg effect). This alteration in metabolism is beneficial for growing cells in many ways that promote tumor growth and suppress the anti-cancer immune response. This specific metabolism is an auspicious target for the better development of cancers chemotherapies.My thesis work comprises two parts. The first portion describes that when cancer cells are forced to utilize their mitochondria in order to obtain the energy from OXPHOS they initiate an antioxidant mechanism to cope with the deleterious effects of reactive oxygen species (ROS) produced during mitochondrial activity. Mitochondrial stimulation leads to activation of ERK5-MEF2 signaling pathway, which triggers the antioxidant mechanism by at least two ways.Initially we observed that MEF2 up regulates the expression of miR23a, which inhibits KEAP1 expression. This protein is responsible for ubiquitinational degradation of NRF2, a master regulator of the antioxidant response in cells. The inhibition of KEAP1 prevents the NRF2 cytoplasmic degradation. This results in high built up of NRF2 in cytoplasm that translocates to nucleus where it binds to ARE (antioxidant response element) in the upstream promoter region of many antioxidant genes hence initiates their transcription. Latter we observed that activation of ERK5-MEF2 pathway directly results in de novo synthesis of NRF2, resulting in nuclear translocation and triggering of the antioxidative mechanism. Inhibition of ERK5-MEF2 pathway impairs the cellular antioxidant response, thus sensitizing cells towards oxidative stress.The second part of my work explored the mechanism behind the lipid lowering effects of dichloroacetate (DCA). DCA is a small molecule, which inhibits the PDK1 and enables pyruvate to enter the mitochondria. It was used clinically in past to lower the plasma cholesterol level but the underlying mechanism was not clear and we describe it here. DCA forces cells to perform OXPHOS, which activate the ERK5-MEF2 pathway. This pathway directly up-regulates the expression of Low Density Lipoprotein Receptors (LDLR) that are mainly involved in the endocytosis of cholesterol-rich low density lipoproteins, which are responsible for the majority of cardiovascular diseases. Inhibition of this pathway suppresses lipid influx and hence, it would be an interesting target of future investigation since high cholesterol level is the main cause of various life threatening diseases and the development of atherosclerosis.Our next goal is to exploit other possible cellular mechanism regulated by ERK5-MEF2 pathway. Based on our preliminary data, we propose that this pathway not only regulate the LDLR expression but many other genes, which are directly or indirectly involved in lipid metabolism.

Les facteurs de transcription Twist1 et Twist2 (famille Twist) jouent un rôle majeur dans le développement embryonnaire et dans la progression tumorale. Leur potentiel oncogénique dérive directement de la combinaison de leurs nombreuses activités développementales. Les gènes Twist peuvent notamment, en induisant la transition épithélio-mésenchymateuse (EMT), promouvoir l’invasion des cellules cancéreuses et participer de ce fait aux processus métastatique. De plus, en bloquant l’activité des voies de signalisation Rb et p53, ils peuvent inhiber les deux principaux programmes de sauvegarde cellulaire que sont l’apoptose et la senescence. Enfin, ils sont également impliqués dans la résistance des cellules cancéreuses aux agents chimio-thérapeutiques. En plus de ces nombreuses activités, nos données préliminaires nous ont amené à considérer un rôle de Twist dans la réponse au stress. Les cellules cancéreuses doivent croitre dans un environnement en perpétuel changement qui génère de nombreux types de stress. Seules les cellules capables de s’adapter, peuvent survivre et acquérir de nouvelles capacités les rendant plus agressives. La résistance au stress fait donc partie intégrante de la progression tumorale. Nos travaux révèlent que Twist en induisant une résistance au stress, plus particulièrement métabolique, est un acteur essentiel de l’acquisition d’u phénotype agressif des cellules cancéreuses. Dans une première étude, nous avons montré que Twist module le stress oxydatif, une condition très fréquemment retrouvée dans les tumeurs. Ainsi, nos résultats indiquent que l’expression de Twist provoque une réduction du taux d’espèces réactives de l’oxygène (ROS) intracellulaire. Cette activité a pour conséquence directe d’induire une résistance accrue à l’apoptose déclenchée par divers traitements. Nous avons par la suite caractérisé cette activité et mis en évidence un programme génétique contrôlé par Twist impliquant divers facteurs possédant des propriétés anti-oxydantes. Dans un second temps, nous nous sommes intéressés à un autre type de stress métabolique, l’hypoxie. L’hypoxie définie par un taux insuffisant d’oxygène, est retrouvée dans la plupart des tumeurs solides du fait de l’absence ou de l’anomalité de la vascularisation. L’hypoxie mène à la stabilisation d’un facteur de transcription, HIF1α. Cette protéine est essentielle à l’adaptation hypoxique et contrôle l’expression de nombreux gènes impliqués dans le métabolisme du glucose, le transport de l’oxygène, l’angiogenèse ou l’apoptose. Dans les premiers temps d’hypoxie, l’effet d’adaptation induit par HIF1α est bénéfique pour les cellules. Cependant, si l’absence d’oxygène se prolonge, HIF1α, peut pousser les cellules vers la mort. Nos travaux démontrent que Twist est capable de rendre les cellules résistantes à une hypoxie prolongée. De plus, cette activité de protection contre le stress hypoxique agit via un effet paracrine. Enfin, nos données suggèrent que cet effet est médié par une interaction directe entre les protéines Twist et HIF1α. Au final, cette étude indique que l’expression de Twist dans les cellules cancéreuses, en conférant une résistance accrue à l’environnement hypoxique, joue un rôle essentiel dans l’adaptation au stress et à l’acquisition de nouveaux phénotypes agressifs. En résumé, L’objectif principal de ma thèse était de mettre en évidence de nouvelles propriétés cellulaires des oncogènes de la famille Twist. Nos résultats démontrent que Twist par ses capacités à contrôler le stress métabolique, permet à la cellule cancéreuse de mieux s’adapter et donc survivre dans un environnement en constante évolution. Nos travaux renforcent donc la notion de l’importance de ces facteurs dans la progression tumorale. / Twist1 and Twist2 are related transcription factors that play major roles both during embryonic development and in several pathologies, including cancer. Twists' oncogenic potential arises from a combination of their multiple functions in development. Notably, both Twist induce epithelial-to mesenchymal transition, thus promoting tumour invasiveness and possibly conferring to cells self-renewal properties. Furthermore, through disruption of both Rb- and p53-driven pathways, Twist override two major oncogene-induced fail-safe programs, namely senescence and apoptosis, thereby promoting malignant conversion. Twist has also been reported to participate in acquisition of drug resistance and in promotion of neo-angiogenesis.Current knowledge of pleiotropic activities of Twist prompted us to postulate that these factors may be major regulators of stress response. Cancer cells survive and grow within a continuously changing environment that creates multiple stresses to which they must adapt in order to survive and strive. Such adaptations often give rise to the acquisition of an aggressive phenotype. Consistent with this hypothesis, we recently unveiled new activities of Twist proteins that are related to stress response. We have shown that Twist regulates response to oxidative stress, a condition exacerbated in cancer by stimuli such as inflammation, increased cellular metabolism and changes in tumour oxygenation. Our work has contributed to the understanding of molecular mechanisms through which Twist diminishes cellular ROS and thus participates in the escape from apoptosis and senescence. In the first part of my thesis, I worked on the antioxidant activity of Twist and described its molecular mechanisms.The second part of my work addressed the impact of Twist proteins on cellular response to hypoxia that is insufficient oxygen supply, frequently found in solid tumours. Cellular response to hypoxic stress relies on stabilization and activation of HIF1α, a key transcriptional mediator of the hypoxic response, regulating numerous genes involved in glucose metabolism, oxygen transport, angiogenesis, cell growth and apoptosis. HIF1α is beneficial for cancer cells in response to short hypoxic episodes, however its sustained activation in case of prolonged hypoxia may push cancer cells towards apoptosis. In this context, we have shown that Twist protects cancer cells from hypoxia-induced apoptosis. We have discovered HIF1α and Twist physically interact, suggesting a possible mechanistic basis for Twist's protective effect. These results led us to postulate that Twist plays a role in cellular response to hypoxia and thus participates in cancer cell adaptation and acquisition of aggressive phenotypes triggered by lack of oxygen.Our results reinforce the notion that Twist factors are major cellular stress modulators that might be important for adaptation of cancer cells to changing conditions in the process of tumour progression.

The B cell population is one of the key components of the adaptive immune system, which protects the host from a tremendous variety of pathogens by producing antibodies. B cells develop from hematopoietic stem cells through a pathway known as B lymphopoiesis. This is a process accompanied by intensive gene expression reprogramming. By the end, genes appropriate for the B lineage are activated and those that are not are continuously repressed. The regulation of lineage gene expression is conferred by a network of transcriptional regulators. Although some key components have been defined, more factors, especially those orchestrating the repression of non-B lineage genes, remain to be identified. Chemically induced mutagenesis is a potent way of identifying genes with critical biological functions. Injection of n-ethyl-n-nitrosourea, a mutagen, has generated a unique point mutation in the mouse Gon4-like (Gon4l) gene that specifically causes a loss of peripheral B cells while maintaining the T cell population. The mutation is therefore named Justy for Just T cells. The goal of this thesis project is to analyze the Justy mice and provide insights into the mechanisms underlying the regulation of B lymphopoiesis. The work presented here demonstrates that the protein encoded by Gon4l is essential for early B lymphopoiesis, which is likely through the repression of non-B lineage genes. Gon4l protein contains conserved domains implicated in transcriptional repression and associates in a complex with the transcriptional repression mediators Yin Yang 1 and Sin3a/HDAC1, after these proteins are transiently expressed in cell lines. When bound to DNA, Gon4l is capable of repressing a nearby promoter and this function correlates with its ability to form a complex. Therefore, these results suggest that Gon4l may function as a transcriptional regulator by employing its associated co-factors in the identified complex. Lastly, a wide spectrum of tumors developed in Justy mice, indicating that Gon4l can also act as a tumor suppressor.

Nous avons souhaité, dans ce travail de Thèse, préciser l'impact de l'invalidation d'AIP sur la fonction sécrétoire et la prolifération des cellules somatotropes in vivo et explorer in vitro les voies de signalisation potentiellement impliquées dans la tumorigenèse hypophysaire AIP-dépendante. L'analyse du phénotype des souris Aip+/-, en particulier de la sécrétion pulsatile de GH, montre que, contrairement à l'Homme, les animaux mutés ne développent pas de gigantisme ni d'hypersécrétion de GH et que la pénétrance de la pathologie tumorale hypophysaire est beaucoup plus faible qu'initialement décrit. Les études réalisées sur les fibroblastes de patients mutés pour AIP et porteurs d'un adénome hypophysaire ainsi que sur les cellules somatolactotropes de rat GH3 révèlent que les mutations d'AIP altèrent l'activité transcriptionnelle d'AhR (Aryl hydrocarbon Receptor), mais affectent également la voie de signalisation de l'AMPc. Enfin, des mutations germinales du gène GPR101, récemment identifiées dans des cas d'acromégalie sporadique, ont aussi été trouvées chez des patients porteurs d'un adénome hypophysaire sporadique non somatotrope, sans association avec les mutations d'AIP. Ce travail a ainsi permis de préciser les conséquences des mutations d'AIP sur la fonction somatotrope et la signalisation d'AhR. Le rôle de l'AMPc dans la tumorigenèse hypophysaire AIP-dépendante sera évalué dans un nouveau modèle de souris transgénique. / In this work, we investigated the effects of AIP deficiency in vivo on somatotroph cells, both at the secretory and proliferative levels and explored in vitro the signaling pathways potentially involved in AIP-dependent pituitary tumorigenesis. Phenotype analyzes of Aip+/- mice, especially of GH pulsatility, show that, unlike humans, mutant mice do not develop gigantism nor GH hypersecretion and present with a much lower penetrance of pituitary adenomas than initially described. In vitro studies in fibroblasts of AIP-mutation positive patients with pituitary adenomas and in somatolactotroph GH3 cells demonstrate that AIP mutations alter AhR (Aryl hydrocarbon Receptor) transcriptional activity and modify the cAMP pathway. Finally, GPR101 mutations, recently reported in patients with sporadic acromegaly, have also been identified in a small portion of patients with sporadic non-somatotroph pituitary adenomas, without any association with AIP mutations. This research work defines the consequences of AIP mutations on somatotroph cell function and AhR transcriptional activity. The role of cAMP signaling in AIP-related pituitary tumorigenesis will be further evaluated in a new transgenic mouse model.